Advances in targeted therapies for Parkinson's disease

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease. Although dopamine replacement therapy is the golden standard of PD treatment, there are limitations due to drug⁃related motor complications and loss of long⁃term efficacy. In the recent two decades, rapid advances in the genetics of PD have made it possible to develop disease⁃modifying therapies. The development of targeted drugs blocking involved pathogenic pathways has become a hot research area in PD. This review summarizes the recent advances in targeted therapies based on three genetic mutations of SNCA, GBA and LRRK2 for PD and involved pathways to improve clinicians' understanding on the precision treatment in PD.

DOI：10.3969/j.issn.1672⁃6731.2019.11.016